Artritis psoriásica

1. Coates LC and Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond) 2017; 17:

65–70.

2. FitzGerald O, Ogdie A, Chandran V, et al. Psoriatic arthritis. Nat Rev Dis Primers 2021; 127: 59.

3. Moll JM and Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 55–78.

4. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54:2665–2673.

5. D'Angelo S, Tramontano G, Gilio M, et al. Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders. Open Access Rheumatol 2017; 9: 21–28.

6. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64: ii14–ii17.

7. Taylor WJ, Marchesoni A, Arreghini M, et al. A comparison of the performance characteristics of classification criteria for the diagnosis of psoriatic arthritis. Semin Arthritis Rheum 2004; 34: 575–584.

8. Punzi L, Podswiadek M, Oliviero F, et al. Laboratory findings in psoriatic arthritis. Reumatismo 2007; 59: 52–55.

9. Su YJ. Early diagnosis of psoriatic arthritis among psoriasis patients: clinical experience sharing. Clin Rheumatol 2020; 39: 3677–3684.

10. Abji F, Pollock RA, Liang K, et al. Brief report: CXCL10 is a possible biomarker for the development of psoriatic arthritis among patients with psoriasis. Arthritis Rheumatol 2016; 68: 2911–2916.

11. Haroon M, Gallagher P and FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and Functional outcome in psoriatic arthritis. Ann Rheum Dis 2015; 74: 1045–1050

12. Coates LC, Strand V, Wilson H, et al. Measurement properties of the minimal disease activity criteria for psoriatic arthritis. RMD Open 2019; 5: e001002.

13. NICE Guidance. Psoriasis. QS40, https://www. nice.org.uk/guidance/qs40

14. Mease PJ, Gladman DD, Helliwell P, et al. Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol 2014; 71: 649–655.

15. van de Kerkhof PC, Reich K, Kavanaugh A, et al. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. J Eur Acad Dermatol Venereol 2015; 29: 2002–2010.

16. Betteridge N, Boehncke WH, Bundy C, et al. Promoting patient-centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience. J Eur Acad Dermatol Venereol 2016; 30: 576–585.

17. Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018rican College of Rheumatology/ National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol 2019; 71: 5–32.

18. Holland R. Psoriatic arthritis is associated with diagnostic delay and worse outcome at three months when compared to rheumatoid arthritis. Ann Rheum Dis 2017; 76: 685.

19. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019ate. Ann Rheum Dis 2020; 79: 700–712.

20. Gratacós J, Behrens F, Coates LC, et al. A 12-point recommendation framework to support advancement of the multidisciplinary care of psoriatic arthritis: a call to action. Joint Bone Spine 2021; 88: 105175.

21. Audureau E, Roux F, Lons Danic D, et al. Psoriatic arthritis screening by the dermatologist: development and first validation of the ‘PURE-4 scale’. J Eur Acad Dermatol Venereol 2018;32: 1950–1953.

22. Torrente-Segarra V, Reina D, Roig D, et al. AB0830cordance of  the Pase Questionnaire (Psoriatic Arthritis Screening Evaluation) for the screening and assessment of clinical practice in psoriatic arthritis. Ann Rheum Dis 2015; 74: 1178.

23. Helliwell PS. Psoriasis  epidemiology screening tool (PEST): a report from the GRAPPA 2009ual meeting. J. Rheumatol 2011; 38: 551–552.

24. Sørensen J, Hetland ML; and all departments of rheumatology in Denmark. Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 2015; 74: e12.

25. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356:  385–390.

26. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebocontrolled PSUMMIT 1 trial. Lancet 2013; 382:780–789.

27. McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human antiinterleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebocontrolled, phase II proof-of-concept trial. Ann Rheum Dis 2014; 73: 349–356.

28. Gossec L, de Wit M, Kiltz U, et al. A patientderived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis 2014; 73: 1012–1019.

29. Coates LC, Soriano E, Corp N, et al. OP0229 Group For Research And Assessment Of Psoriasis And Psoriatic Arthritis (Grappa) Treatment Recommendations 202. Ann Rheum Dis 2021; 80: 139–140.

30. Raja K, Dasot N, Goyal P, et al. Towards evidence-based precision medicine: extracting population information from biomedical text using binary classifiers and syntactic patterns. AMIA Jt Summits Transl Sci Proc 2016; 2016:203–212.

31. Dobbin-Sears I, Roberts J, O'Rielly DD, et al. Ustekinumab in psoriatic arthritis and related phenotypes. Ther Adv Chronic Dis 2018; 9:191–198.

32. Naik GS, Ming WK, Magodoro IM, et al. Th17 inhibitors in active psoriatic arthritis: a systematic review and meta-analysis of randomized controlled clinical trials. Dermatology 2017; 233:366–377.

33. Miyagawa I, Nakayamada S, Nakano K, et al. Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatology (Oxford) 2019; 158: 336–344.